Abstracts tagged "interstitial lung disease and mycophenolate mofetil"

Abstract Number: 1568 • 2018 ACR/ARHP Annual Meeting
Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study
Barkha Amlani¹, Umang Barvalia², Ghada Metwally Ahmed Elsayed³, Jeffrey P. Kanne⁴, Zhanhai Li⁵ and Sara S. McCoy⁶, ¹Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pulmonary And Critical Care, university of wisconsin Hospital and clinics, Madison, WI, ³Rheumatology, University of Wisconsin Hospital and clinics, Madison, WI, ⁴Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Interstitial lung disease (ILD) is a common extraglandular manifestation of Sjögren’s syndrome (SS). There is a paucity of literature on the management of SS-ILD.…
Abstract Number: 1171 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil May Improve Interstitial Pneumonia with Autoimmune Features
Sara S. McCoy¹, Zubin Mukadam², Keith C. Meyer³, Emmanuel Sampene⁴, Jeffrey P. Kanne⁵, Christopher A. Meyer⁵, Maria D. Martin⁵, Scott W. Aesif⁶, Laurie Rice⁷ and Christie M. Bartels⁸, ¹Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²PULMONARY & CRITICAL CARE, University of Wisconsin School of Medicine and Public Health, madison, WI, ³PULMONARY & CRITICAL CARE, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, madison, WI, ⁷Critical Care Medicine, SSM Health Dean Medical Group, madison, WI, ⁸Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: To assess the efficacy of mycophenolate mofetil (MMF) in treatment of adult patients with interstitial pneumonia with autoimmune features (IPAF). Methods: A retrospective medical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].